1 / 25

Non-alcoholic Steatohepatitis

Eric Tibesar, MD Ann Scheimann, MD, MBA Johns Hopkins Children’s Center Reviewed by John Stutts, MD of the Professional Education Committee. Non-alcoholic Steatohepatitis. Case Presentation. 12 year old male presents to your pediatric GI clinic with complaints of abdominal pain

mroberto
Télécharger la présentation

Non-alcoholic Steatohepatitis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Eric Tibesar, MD Ann Scheimann, MD, MBA Johns Hopkins Children’s Center Reviewed by John Stutts, MD of the Professional Education Committee Non-alcoholic Steatohepatitis

  2. Case Presentation • 12 year old male presents to your pediatric GI clinic with complaints of abdominal pain • Pain has been persistent for the last 6 months, mainly epigastric without radiation • He denies nausea, vomiting, and his stools have been irregular but soft without diarrhea • Diet consists of high carb, high fat and low protein meals with multiple snacks daily

  3. Case Presentation • Growth measurements • Height 160 cm (91st percentile for age) • Weight 95 kg (>99th percentile for age) • BMI 37.1 (>99th percentile for age, z score +2.6) • Physical exam • Marked abdominal obesity with striae, acanthosis nigricans noted on back of neck, liver palpated 3 cm below costal margin, otherwise normal exam

  4. Case Presentation • Screening laboratory markers • Negative celiac and thyroid studies • Electrolytes and CBC normal • INR 1.1, AST 52 IU/L, ALT 62 IU/L, T.bili 1.1 mg/dL, fasting glucose 135 mg/dL, serum insulin 32 μU/mL(normal 2.6-24.4 μU/mL) • Imaging • Abdominal ultrasound read: • Hepatomegaly with increased echogenicity, normal gallbladder and spleen

  5. Case Presentation • Liver biopsy • Macrovesicular steatosis, diffuse inflammation, ballooning hepatocytes with Mallory-Denk/hyaline bodies

  6. Definition “Lipid deposition in hepatocytes in individuals who drink little or no alcohol” Hepatic Steatosis-fatty liver, fat accumulation in >5% hepatocytes ↓ Nonalcoholic steatohepatitis (NASH) – fatty changes with inflammation and hepatocellular injury or fibrosis ↓ advanced fibrosis and cirrhosis

  7. Epidemiology • One of the leading indications for liver transplantation in adults in the United states • Adults: • NAFLD 20-30% population in Western countries • NASH: 3% adults and 20% obese people • Children: • NAFLD: 3-10% in Western countries • Obese children: 23-77%

  8. Epidemiology • Boys 40% > Girls • Ages 2-17 years (avg 12 years) • Autopsy data: • Fatty liver in 9.6% of 742 pediatric autopsies • Fatty liver: Hispanic 12%, Asian 10.2%, White 8.6%, African-American 1.5% • Fatty liver in 38% of obese children • NASH in 3% (23% of the subjects with fatty liver) Patton et al, JPGN 2006;43:413 Schwimmer et al, Pediatrics 2006;118(4):1388

  9. Pathophysiology • ‘Two hit’ hypothesis • First hit: Hepatic steatosis is caused by insulin resistance: • Leptin may stimulate inflammation, fat storage • Adiponectin is anti-inflammatory, anti-steatotic • Levels of free fatty acid uptake and synthesis, with subsequent esterification to triglycerides (termed ‘input’), is greater than the levels of FFA oxidation and secretion (termed ‘output’)

  10. Pathophysiology Alisi et al, Nat. Rev. Gastroenterol. Hepatol. 9, 152-161 (2012)

  11. Pathophysiology • Second hit: • Several factors promote oxidative stress (along side FFA and insulin resistance) • Proinflammatory cytokines • Mitochondrial dysfunction • Adiponectin (produced by a adipocytes) • Lipotoxicity: Direct toxicity to hepatocytes (lipid peroxidation) • Bacterial endotoxins • Stellate cell activation/mediators of fibrosis

  12. Presentation • Signs and symptoms • Most often asymptomatic, discovered incidentally with elevation of liver enzymes • Common symptoms: • Malaise • Fatigue • RUQ/diffuse abdominal pain

  13. Presentation • Hepatomegaly (33-55%) • Acanthosis nigricans (30%) - more common in children than adults • Usually obese • Have associated features of metabolic syndrome • Insulin resistance in most patients • Impaired glucose tolerance (10%) • Type 2 diabetes (2%) • Variable incidence of hyperlipidemia and hypertension • Cirrhosis – stigmata of chronic liver disease

  14. Diagnosis • Diagnosis of exclusion • Rule out other causes of transaminase elevation and fatty liver • Careful history and physical examination • Ask about alcohol consumption • Enquire about other causes of liver disease • Drugs (illicit or prescribed), viral hepatitis, family history of liver disease, nutrition

  15. Differential diagnosis Wyllie et al, (2006) Pediatric Gastrointestinal and Liver Disease 3rd Ed. Philidelphia, PA; Elsevier

  16. Diagnostic work-up • Other diseases to screen for: • Hepatitis B, C • Autoimmune hepatitis (some children with NAFLD have positive antibodies) • Wilson’s disease • A1AT deficiency • +/- screening inborn errors metabolism • Baseline laboratory evaluations: • Transaminases • 4-6x upper limit of normal but variable • AST:ALT <1, ratio increased as fibrosis advances • Normal levels do not exclude presence of fibrosis/cirrhosis • Total and direct bilirubin • GGT • Fasting serum glucose, insulin and lipid panel

  17. Be careful of lab values • Regional laboratories use local population for norms • do not exclude overweight/obese or other causes of liver disease • Median ULN at children’s hospitals 53 U/L (range 30‐90) • Too high to detect chronic liver disease (sensitivity 32‐42%) • 95th percentile for ALT in healthy weight, metabolically normal, liver disease free, NHANES adolescent group (12‐17 yrs) • Persistently 2 x ULN (45‐50 U/L) may be the threshold for more screening Schwimmer JB. Gastroenterology 2010;138:1357

  18. Diagnostic work-up • Imaging • Ultrasound • Most commonly used • Diffuse increase in echogenicity and vascular blurring • Cannot rule out steatohepatitis/fibrosis • Sensitivity drops when degree of steatosis <30% • Lower sensitivity in morbidly obese patients • CT and MRI more sensitive for quantification of steatosis • Poor sensitivity and specificity for staging of disease

  19. Alisi et al, Nat. Rev. Gastroenterol. Hepatol. 9, 152-161 (2012)

  20. Liver biopsy findings • Steatosis • >5% hepatocytes • mainly macrovesicular • Inflammation • Inflammatory infiltrate including lymphocytes, histiocytes and Kupffer cells • Ballooning Hepatocytes • Cytoplasm can contain Mallory-Denk/hyaline bodies • Fibrosis Weingarten, et al OBES SURG (2011) 21:1714–1720

  21. NAFLD ACTIVITY SCORE (NAS) • Range 0-8 • Individual scores for: • Steatosis (0-3) • Lobular inflammation (0-3) • Ballooning (0-2) • NAS: • <3 – not NASH • >5 Definite NASH • Does not take into account portal injury in pediatric patients and often underestimates scores

  22. Liver biopsy findings • Two subtypes described in biopsy specimens: • Type 1 NASH: steatosis with ballooning degeneration of hepatocytes and perisinusoidal fibrosis • Type 2 NASH: steatosis with portal inflammation and/or portal fibrosis without evidence of ballooning degeneration

  23. Treatment • No one medicine proven to be effective • Treat associated risk factors – obesity, OSA, type 2 diabetes • Lifestyle changes are most effective • Diet and Exercise • Weight reduction shown to improve biochemical parameters and liver histology • Avoid rapid weight loss as may accelerate inflammation • Avoid alcohol

  24. Treatment • Pharmacologic Therapy • Insulin sensitizers (metformin) • No more effective than lifestyle changes for biochemical and liver histology parameter • Antioxidants (Vitamin E +/- Vitamin C) • Not superior to placebo • Vitamin E was shown to reduce ballooning of hepatocytes • Docosahexaenoic acid • Promising preliminary results • No current pediatric recommendations

  25. Treatment • Surgical: • Bariatric surgery • Adult studies show improvement in histology but no analogous pediatric studies • Liver transplantation • Indicated in patients with decompensated cirrhosis • NAFLD can recur in allograft, and progress to steatohepatitis

More Related